1 Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin J, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I: The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J THORAC ONCOL 2015;10:1243-1260.
2 Tot T: Cytokeratins 20 and 7 as biomarkers: Usefulness in discriminating primary from metastatic adenocarcinoma. EUR J CANCER 2002;38:758-763.
3 Moll R, Schiller DL, Franke WW: Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J CELL BIOL 1990;111:567-580.
4 Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C: CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. AM J SURG PATHOL 2003;27:141-149.
5 Wang CX, Liu B, Wang YF, Zhang RS, Yu B, Lu ZF, Shi QL, Zhou XJ: Pulmonary enteric adenocarcinoma: A study of the clinicopathologic and molecular status of nine cases. Int J Clin Exp Pathol 2014;7:1266-1274.
6 Nottegar A, Tabbò F, Luchini C, Brunelli M, Bria E, Veronese N, Santo A, Cingarlini S, Gilioli E, Ogliosi C: Pulmonary adenocarcinoma with enteric differentiation: Immunohistochemistry and molecular morphology. APPL IMMUNOHISTO M M 2018
7 Dragomir A, de Wit M, Johansson C, Uhlen M, Ponten F: The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. AM J CLIN PATHOL 2014;141:630-638.
8 Hatanaka K, Tsuta K, Watanabe K, Sugino K, Uekusa T: Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: A report of the second case negative for cytokeratin 7. PATHOL RES PRACT 2011;207:188-191.
9 Sauter ER, Bolton JS, Willis GW, et al. Improved survival after pulmonary resection of metastatic colorectal carcinoma[J]. J SURG ONCOL, 1990, 3(43): 135-138.
10 Olga B, Sergey A, Sergey L, Peter G, Victor T: Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. EUR J NEUROSCI 2015;21:658-668.
11 Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, Wester K, Gry M, Bjartell A, Gallagher WM, Rexhepaj E, Kilpinen S, Kallioniemi OP, Belt E, Goos J, Meijer G, Birgisson H, Glimelius B, Borrebaeck CA, Navani S, Uhlen M, O'Connor DP, Jirstrom K, Ponten F: SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. AM J SURG PATHOL 2011;35:937-948.
12 Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjostedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlen M: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. MOL CELL PROTEOMICS 2014;13:397-406.
13 Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH: Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. AM J SURG PATHOL 2013;37:1532-1541.
14 Lugli A, Tzankov A, Zlobec I, Terracciano LM: Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008;21:1403-1412.
15 Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A: Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J PATHOL 2011;225:336-343.
16 McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR: Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. AM J SURG PATHOL 2004;28:712-718.
17 Gurzu S, Jung I: Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. PATHOL RES PRACT 2012;208:163-166.
18 Gurzu S, Szentirmay Z, Toth E, Bara T, Bara TJ, Jung I: Serrated pathway adenocarcinomas: Molecular and immunohistochemical insights into their recognition. PLOS ONE 2013;8:e57699.
19 Ma C, Olevian DC, Lowenthal BM, Jayachandran P, Kozak MM, Chang DT, Pai RK: Loss of SATB2 expression in colorectal carcinoma is associated with DNA mismatch repair protein deficiency and BRAF mutation. AM J SURG PATHOL 2018;42:1409-1417.
20 Osoegawa A, Kometani T, Fukuyama S, Hirai F, Seto T, Sugio K, Ichinose Y: Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma. Ann Thorac Cardiovasc Surg 2016;22:6-11.
21 Matsushima J, Yazawa T, Suzuki M, Takahashi Y, Ota S, Nakajima T, Yoshino I, Yokose T, Inoue T, Kawahara K, Nakatani Y: Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: Usefulness of SATB2 and beta-catenin immunostaining for differentiation from metastatic colorectal carcinoma. HUM PATHOL 2017;64:179-185.
22 Bian T, Zhao J, Feng J, Zhang Q, Qian L, Liu J, Jiang D, Liu Y, Zhang J: Combination of Cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget 2017
23 Kriegsmann M, Harms A, Longuespee R, Muley T, Winter H, Kriegsmann K, Kazdal D, Goeppert B, Pathil A, Warth A: Role of conventional immunomarkers, HNF4-alpha and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas. HISTOPATHOLOGY 2018;72:997-1006.